Baseline demographics and clinical characteristics of donors and patients with COVID-19 or ARDS-influenza who provided plasma samples
| . | Hanover cohort . | Berlin cohort . | ||||
|---|---|---|---|---|---|---|
| ARDS-influenza . | COVID-19 (WHO 5-7) . | Donor . | COVID-19 (WHO 5-7) . | COVID-19 (WHO 3-4) . | Donor . | |
| Patients, n | 25 | 21 | 21 | 15 | 15 | 15 |
| Age, y [range] | 56 [20-86] | 59 [19-82] | 60 [20-79] | 61 [22-84] | 61 [26-80] | 61 [24-82] |
| Sex, male, % | 87 | 90 | 88 | 69 | 67 | 68 |
| BMI [range], kg/m2 | 25 [20-36] | 29 [15-62] | 26 [19-45] | 29 [25-36] | 24 [20-36] | 25 [22-37] |
| 65 score | ||||||
| 0 | 0 | 0 | — | NA | NA | — |
| 1 | 3 | 2 | — | NA | NA | — |
| 2 | 5 | 6 | — | NA | NA | — |
| 3 | 12 | 9 | — | NA | NA | — |
| 4 | 5 | 4 | — | NA | NA | — |
| 28-d mortality, % | 30 | 14.3 | — | 8 | 0 | — |
| LOS ICU, d [range] | 19 [6-73] | 27 [3-63] | — | 30 [5-220] | NA | — |
| Ventilation, d [range] | 15 [3-66] | 16 [4-50] | — | 26 [5-220] | NA | — |
| ECMO, % | 30 | 24 | — | 46 | NA | — |
| SOFA score [range] | 10 [5-16] | 13 [9-17] | — | 10 [2-12] | NA | — |
| CRP, mg/L [range] | 264 [31-406] | 151 [68-292] | — | 85 [27-411] | 29 [1-148] | — |
| Leukocytes, ×109/L [range] | 16 [22-90] | 9 [4-36] | — | 10 [5-27] | 7 [4-22] | — |
| Platelets, ×109/L [range] | 199 [70-653] | 247 [99-581] | — | 286 [129-635] | 334 [173-602] | — |
| Lactate, mM [range] | 1.3 [0.7-4.8] | 1.8 [0.7-5.6] | — | 1.7 [0.4-6.6] | 1.3 [1.0-2.6] | — |
| Procalcitonin, µg/L [range] | 1.7 [0.2-79.5] | 0.6 [0.1-66.1] | — | 0.6 [0.1-25] | 0.1 [0-1] | — |
| d-dimer, mg/L [range] | NA | 4 [1-35] | — | NA | NA | — |
| Fibrinogen, g/L [range] | 4.0 [3.2-9.0] | 8.0 [4.0-9.0] | — | NA | NA | — |
| Anticoagulant | ||||||
| Heparin, n | 15 | 14 | — | 8 | 7 | — |
| PTT, s [range] | 38 [25-59] | 36 [26-55] | — | 41 [30-67] | 34 [30-60] | — |
| . | Hanover cohort . | Berlin cohort . | ||||
|---|---|---|---|---|---|---|
| ARDS-influenza . | COVID-19 (WHO 5-7) . | Donor . | COVID-19 (WHO 5-7) . | COVID-19 (WHO 3-4) . | Donor . | |
| Patients, n | 25 | 21 | 21 | 15 | 15 | 15 |
| Age, y [range] | 56 [20-86] | 59 [19-82] | 60 [20-79] | 61 [22-84] | 61 [26-80] | 61 [24-82] |
| Sex, male, % | 87 | 90 | 88 | 69 | 67 | 68 |
| BMI [range], kg/m2 | 25 [20-36] | 29 [15-62] | 26 [19-45] | 29 [25-36] | 24 [20-36] | 25 [22-37] |
| 65 score | ||||||
| 0 | 0 | 0 | — | NA | NA | — |
| 1 | 3 | 2 | — | NA | NA | — |
| 2 | 5 | 6 | — | NA | NA | — |
| 3 | 12 | 9 | — | NA | NA | — |
| 4 | 5 | 4 | — | NA | NA | — |
| 28-d mortality, % | 30 | 14.3 | — | 8 | 0 | — |
| LOS ICU, d [range] | 19 [6-73] | 27 [3-63] | — | 30 [5-220] | NA | — |
| Ventilation, d [range] | 15 [3-66] | 16 [4-50] | — | 26 [5-220] | NA | — |
| ECMO, % | 30 | 24 | — | 46 | NA | — |
| SOFA score [range] | 10 [5-16] | 13 [9-17] | — | 10 [2-12] | NA | — |
| CRP, mg/L [range] | 264 [31-406] | 151 [68-292] | — | 85 [27-411] | 29 [1-148] | — |
| Leukocytes, ×109/L [range] | 16 [22-90] | 9 [4-36] | — | 10 [5-27] | 7 [4-22] | — |
| Platelets, ×109/L [range] | 199 [70-653] | 247 [99-581] | — | 286 [129-635] | 334 [173-602] | — |
| Lactate, mM [range] | 1.3 [0.7-4.8] | 1.8 [0.7-5.6] | — | 1.7 [0.4-6.6] | 1.3 [1.0-2.6] | — |
| Procalcitonin, µg/L [range] | 1.7 [0.2-79.5] | 0.6 [0.1-66.1] | — | 0.6 [0.1-25] | 0.1 [0-1] | — |
| d-dimer, mg/L [range] | NA | 4 [1-35] | — | NA | NA | — |
| Fibrinogen, g/L [range] | 4.0 [3.2-9.0] | 8.0 [4.0-9.0] | — | NA | NA | — |
| Anticoagulant | ||||||
| Heparin, n | 15 | 14 | — | 8 | 7 | — |
| PTT, s [range] | 38 [25-59] | 36 [26-55] | — | 41 [30-67] | 34 [30-60] | — |
BMI, body mass index; CRB 65, confusion, respiratory rate, blood pressure, age 65 score; LOS ICU, length of intensive care unit stay; ECMO, extracorporeal membrane oxygenation; SOFA, sequential organ failure assessment; PTT, partial thromboplastin time.